bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Zacks News
FDA Grants Priority Review to Global Blood's SCD Candidate
by Zacks Equity Research
The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.
Bluebird (BLUE) Down 19.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
bluebird (BLUE) posts wider-than-expected loss, while sales beat estimates in the second quarter of 2019.
Bluebird Bio (BLUE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of -17.16% and 25.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
bluebird's Zynteglo Gets EU Conditional Marketing Approval
by Zacks Equity Research
bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype.
Why Is Bluebird (BLUE) Down 15.1% Since Last Earnings Report?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
bluebird's (BLUE) Loss Wider Than Expected, Revenues Down Y/Y
by Zacks Equity Research
bluebird (BLUE) reports wider-than-expected Q1 loss. Nevertheless, the pipeline progress looks encouraging.
Bluebird Bio (BLUE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of -6.79% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates
by Zacks Equity Research
So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.
Is a Beat in the Cards for Molina's (MOH) Earnings in Q1?
by Zacks Equity Research
Molina Healthcare's (MOH) Q1 earnings will gain from membership growth and its streamlining efforts. However, the same might be partially offset by contract losses and the company's Marketplace business.
Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Universal Health's (UHS) first-quarter earnings are affected by a pre-tax unrealized loss.
What's in Store for HCA Healthcare's (HCA) Q1 Earnings?
by Zacks Equity Research
HCA Healthcare (HCA) is likely to gain from higher admissions. However, escalating expenses might weigh down its margins.
Is a Beat in Store for WellCare Health's (WCG) Q1 Earnings?
by Zacks Equity Research
WellCare Health's (WCG) first-quarter earnings are likely to gain from a rise in membership, partly offset by high debt load.
Tenet Healthcare (THC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Tenet Healthcare (THC) is likely to be hit by declining revenues in the first quarter of 2019.
Anthem's (ANTM) Q1 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) Q1 earnings surge on the back of a solid operating performance and strong growth across all core businesses.
Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celgene & Acceleron Submit BLA for Luspatercept to the FDA
by Zacks Equity Research
Celgene (CELG) and partner Acceleron submit BLA for pipeline candidate, luspatercept to the FDA.
Global Blood Focuses on Developing Lead Candidate Voxelotor
by Zacks Equity Research
Global Blood (GBT) is fast progressing on the development plans for its lead pipeline candidate, voxelotor for the treatment of sickle cell disease.
Celgene (CELG) Submits NDA for MS Drug to FDA for Review
by Zacks Equity Research
Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.
Why Is Bluebird (BLUE) Up 15.3% Since Last Earnings Report?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celgene (CELG) Submits Application for MS Drug in Europe
by Zacks Equity Research
Celgene (CELG) submits application for MS drug, ozanimod to the European Medicines Agency.
Biotech ETFs Jump on Roche-Spark Deal
by Sweta Killa
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
bluebird (BLUE) reports narrower-than-expected Q4 loss. The pipeline progress looks encouraging.
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 3.89% and 96.00%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?